Prognostic and Predictive Role of Circulating Tumor DNA in Locally Advanced Rectal Cancer Managed With Total Neoadjuvant Therapy: A Systematic Review.

Authors

Faizan Bashir, Qurat-Ul-Aine Bhat, Jayden Allegakoen, Dorsa Shekouh, Sajida Zaiter

Published in

Health science reports. Volume 9. Issue 8. Pages e72905. Epub Jul 28, 2026.

Abstract

Circulating tumor DNA (ctDNA) has emerged as a promising biomarker of tumor burden and minimal residual disease. As total neoadjuvant therapy (TNT) increasingly supports organ-preserving strategies in locally advanced rectal cancer (LARC), reliable markers of treatment response are needed. This review evaluates the prognostic and predictive value of ctDNA in this setting.
Following PRISMA guidelines, we systematically reviewed studies across PubMed/MEDLINE, Web of Science, Cochrane and Google Scholar evaluating ctDNA during or after TNT in LARC reporting treatment-response or survival outcomes.
Seven studies met inclusion criteria. Baseline ctDNA detection was near-universal (83-100%) but lacked discriminatory value. ctDNA declined progressively during TNT, with post-TNT negativity correlating with clinical or pathological complete response (p = 0.007-0.038). Persistent positivity predicted residual disease and inferior survival (DFS HR 4.03; OS HR 23.0), with presurgical ctDNA in GEMCAD showing preferential association with hepatic recurrence suggesting a marker of systemic rather than locoregional disease. Post-TNT ctDNA demonstrated high specificity but low sensitivity (23%-45%) for residual disease, and preceded clinical recurrence detection by weeks to months.
ctDNA clearance at the end of TNT may represent a biologically meaningful marker of treatment response and recurrence risk. However, current data derive from small, heterogeneous cohorts with variable assay platforms and sampling schedules, and ctDNA's limited sensitivity precludes its use as a standalone tool for non-operative management selection.

PMID:
42524649
Bibliographic data and abstract were imported from PubMed on 29 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.